These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 10219506)

  • 1. Selective imidazoline receptor agonists and lipid metabolism.
    Elisaf M; Tselepis A; Siamopoulos K
    Clin Chem Lab Med; 1999 Feb; 37(2):165. PubMed ID: 10219506
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective imidazoline receptor agonists for metabolic syndrome.
    Krentz AJ; Evans AJ
    Lancet; 1998 Jan; 351(9097):152-3. PubMed ID: 9449863
    [No Abstract]   [Full Text] [Related]  

  • 3. [Imidazoline receptor agonists in the practical treatment of hypertension].
    Ol'binskaia LI; Bochenkov IuV; Alekseeva IL
    Ter Arkh; 1998; 70(2):86-8. PubMed ID: 9551585
    [No Abstract]   [Full Text] [Related]  

  • 4. [Agonists of the imidazoline receptors].
    Ol'binskaia LI; Bochenkov IuV
    Eksp Klin Farmakol; 1999; 62(2):68-72. PubMed ID: 10340136
    [No Abstract]   [Full Text] [Related]  

  • 5. [The significance of the sympathetic nervous system during therapy for hypertension and related pathologies. Imidazoline-I1-receptor agonists. 17th Scientific Meeting of the International Society of Hypertension. Amsterdam, June 7, 1998].
    Dtsch Med Wochenschr; 1998 Aug; 123(33 Suppl):1-4. PubMed ID: 9739350
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacology of moxonidine: an I1-imidazoline receptor agonist.
    Ernsberger P
    J Cardiovasc Pharmacol; 2000; 35(7 Suppl 4):S27-41. PubMed ID: 11346217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Central nervous system as a target for the new antihypertensive agents].
    Nurminen ML
    Duodecim; 1999; 115(20):2267-73. PubMed ID: 11973931
    [No Abstract]   [Full Text] [Related]  

  • 8. [New trends in the treatment of arterial hypertension: identification of the I1 receptor and the pharmacology of imidazoline].
    Pavlović P
    Vojnosanit Pregl; 1998; 55(3):305-10. PubMed ID: 9720446
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective stimulation of I1-imidazoline receptors as a novel mechanism for antihypertensive action. Focus on moxonidine.
    Papp JG; Ollivier JP
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():v-vi. PubMed ID: 7533220
    [No Abstract]   [Full Text] [Related]  

  • 10. [Imidazole receptor agonists--a new advance in the treatment of hypertension?].
    Spinar J; Vítovec J
    Vnitr Lek; 2000 Feb; 46(2):122-5. PubMed ID: 11048538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term antihypertensive therapy with moxonidine (cynt) in patients with insulin-independent diabetes mellitus].
    Lazebnik LB; Malichenko SB; Serebrov AN
    Ter Arkh; 1997; 69(6):59-64. PubMed ID: 9297279
    [No Abstract]   [Full Text] [Related]  

  • 12. Imidazoline I1 receptor agonists: new data on hypertension and related pathologies: introduction.
    Fernandez-Cruz A
    J Hypertens Suppl; 1997 Jan; 15(1):S1-2. PubMed ID: 9050979
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical assessment of prolonged therapy of patients with hypertension and diabetes with imidazoline receptor agonist moxonidine].
    Trusov VV; Aksenov KV; Filimonov MA
    Kardiologiia; 2002; 42(2):50-3. PubMed ID: 12494208
    [No Abstract]   [Full Text] [Related]  

  • 14. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):359-67. PubMed ID: 15025845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites.
    Ernsberger P; Damon TH; Graff LM; Schäfer SG; Christen MO
    J Pharmacol Exp Ther; 1993 Jan; 264(1):172-82. PubMed ID: 8380858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxonidine: a review of safety and tolerability after seven years of clinical experience.
    Schachter M
    J Hypertens Suppl; 1999 Aug; 17(3):S37-9. PubMed ID: 10489097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress in the research on imidazoline receptors].
    Dai SM; Shan ZZ; Su DF
    Sheng Li Ke Xue Jin Zhan; 1997 Jul; 28(3):283-5. PubMed ID: 11038747
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative study of NMDA and AMPA/kainate receptors involved in cardiovascular inhibition produced by imidazoline-like drugs in anaesthetized rats.
    Wang LG; Zeng J; Yuan WJ; Su DF; Wang WZ
    Exp Physiol; 2007 Sep; 92(5):849-58. PubMed ID: 17573415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.